CHEST SEEK® Peer Review Discussions-Improved Asthma Control

Video Transcription

Video Summary

In this video, the speaker discusses the use of different therapies for patients with severe asthma. They mention that it may not be necessary to use oral corticosteroids as a controller therapy, especially if the patient doesn't have frequent exacerbations. The speaker also talks about the use of immune modulators and emphasizes the importance of considering the patient's inflammatory response, preferences, and prescription plan coverage when selecting a therapy. They mention the lack of high-level evidence to guide clinical decision-making in choosing biologics for severe asthma and the need for further research in this area. The speaker suggests considering dupilumab as a reasonable alternative for a patient with severe asthma who is steroid-dependent, but also mentions the possibility of using other biologics depending on the patient's individual characteristics and needs. They discuss the importance of understanding the mechanism of action of different biologics and the potential limitations of relying on markers of eosinophilic inflammation as predictors of responsiveness. Overall, the speaker encourages a personalized approach to treatment selection for patients with severe asthma. <br /><br />This transcription has not presented the names of the speakers, and it is unclear if any credits are necessary.

Asset Caption

Notable commentary from Drs. Andrew Berman, Subani Chandra, and Jesse Hall.

Recorded in December 2022.

Keywords

severe asthma

oral corticosteroids

immune modulators

biologics

dupilumab

personalized approach